Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > Kly ‘s ceo and board is recommending that kly buys a company
View:
Post by edrose on Jun 01, 2020 5:24pm

Kly ‘s ceo and board is recommending that kly buys a company

Which as only one very early product  not even close to being approved and we don't have the money to do the research on r107 and Barca funding is not even close to being approved 
where will kly find the money we can't even do research on our product that only needs phase3 to be done 

how does this make sense this is like the stero deal
Comment by Jack4000 on Jun 01, 2020 5:36pm
This post has been removed in accordance with Community Policy
Comment by Malfuncion on Jun 01, 2020 5:55pm
Where’s this information 
Comment by JMark80 on Jun 01, 2020 7:28pm
I think he meant for Covid, not CILI?
Comment by Jack4000 on Jun 01, 2020 8:41pm
This post has been removed in accordance with Community Policy
Comment by JMark80 on Jun 01, 2020 11:01pm
Salzman is applying for a BARDA contract for COVID. Nobody knows whether or not they will receive it.
Comment by Lubb123 on Jun 01, 2020 11:26pm
I have never witnessed such aggressive  annoying uninformed trolls on a board.  Why do you think they gather here?  Like incels they've found like minded peeps or what. Maybe they make a small living shorting for half pennies every three days  but my god what a way to spend your time.   
Comment by Moonshiner592 on Jun 02, 2020 7:55am
"Incels".... that's got to be the best word to call these trolls that spew BS on this board 24/7!!  .. because that's what they are!    Lubb - nicely done!  
Comment by Jack4000 on Jun 01, 2020 11:35pm
This post has been removed in accordance with Community Policy
Comment by JMark80 on Jun 02, 2020 12:04am
Having a contract for a different indication doesn't increase their chances. They really can't afford to pay for a trial without BARDA when there are many promising vaccines in development, and latest PR sounds like they are proceeding regardless. Still think CEO is a cuck, constantly changing pipeline, two terrible failed acquisitions, the potential reverse split, the botched IIA grant ...more  
Comment by Jack4000 on Jun 02, 2020 12:28am
This post has been removed in accordance with Community Policy
Comment by JMark80 on Jun 02, 2020 11:31am
I'm soooo scared! Golly!!!!! LMAO
Comment by Jack4000 on Jun 02, 2020 11:52am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities